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Abstract 
Background: Treatment of acute organophosphorus (OP) insecticide poisoning is difficult, with many 
patients dying despite best care. Pre-clinical studies have shown benefit from salbutamol, possibly due 
speeding alveolar fluid clearance or reducing bronchoconstriction. In this small pilot dose-response 
study, we aimed to explore whether addition of nebulised salbutamol to standard care might improve 
resuscitation. 
Methods: We performed a single-blind phase II study comparing the effect of two different doses of 
nebulized salbutamol versus saline placebo, in addition to standard treatment. Primary outcome was 
oxygen saturations over the first 60 min of resuscitation; secondary outcomes included heart rate, 
incidence of dysrhythmias, time to ‘atropinisation’, atropine dose required, and mortality.  
Result: Seventy-five patients were randomised to receive 5 mg (Salb5, n=25) or 2.5mg (Salb2.5, n=25) 
of salbutamol, or saline placebo (NoSalb, n=25), by nebuliser. Oxygen saturations did not differ 
between groups over the first 60 min of resuscitation (median AUC NoSalb: 1376 [95% CI 1282 to 
1470], Salb2.5: 1395 [1305 to 1486], Salb5: 1233 [1100 to 1367]; p=0.9898). Heart rate was also 
similar across the three arms. Median time to full atropinisation, and atropine dose required, were the 
same for all three arms (NoSalb 15.0 [10-16] min & 12.6 [8.0-13.4] mg, Salb2.5 15.0 [10-16] min & 12.6 
[9.3-16.8] mg, and Salb5 15.0 [10-20] min & 12.6 [10.7-20.6] mg; p=0.4805 and p=0.1871, 
respectively). Three (12%) patients died in the Salb2.5 and Salb5 groups and two (8%) in the NoSalb 
group. 
Conclusion: This pilot study, within the limitations of its small size and variation between patients, 
found no apparent evidence that administration of nebulised salbutamol improved resuscitation of 
patients with acute OP insecticide self-poisoning. The data obtained provides a basis to design further 
studies to ultimately test the role of salbutamol in OP insecticide poisoning. 
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INTRODUCTION 
Self-poisoning with pesticides is one of the three most important global means of suicide,[1] being 
particularly important in lower and middle-income countries (LMIC) where highly hazardous pesticides 
(HHPs) cause over 10,000 deaths each year.[2, 3] Organophosphorus (OP) insecticides are 
responsible for many of these deaths. They inhibit acetylcholinesterase (AChE), causing cholinergic 
overstimulation in the autonomic nervous system, central nervous system and neuromuscular junction 
(NMJ).[4] Patients die early from acute respiratory failure, especially if it occurs before hospital 
presentation, or later from cardiovascular collapse, delayed NMJ dysfunction, or complications of pre-
hospital toxicity (eg. hypoxic brain injury or aspiration pneumonia) and mechanical ventilation.[5-7] 
Acute respiratory failure results from failure of central respiratory drive and NMJ dysfunction, as well as 
bronchorrhoea and bronchoconstriction that cause severe hypoxia.[6, 8]  
 
Medical management is difficult.[9] Mainstays of treatment include immediate resuscitation and oxygen, 
administration of the muscarinic antagonist atropine, and assisted ventilation.[9, 10] Incremental (or 
double) bolus dosing of atropine is highly effective;[11] the role of oxime AChE reactivators, such as 
pralidoxime, is unclear.[12, 13] Case fatality for self-poisoning remains high, especially in the under-
resourced district hospitals that admit the majority of patients worldwide. While regulatory action to 
remove HHPs from agricultural practice is likely to be the most effective public health response [14, 15], 
OP insecticides will continue to be used for the foreseeable future and better treatment options are 
urgently required. 
 
By antagonising muscarinic receptors, atropine turns off the production of the bronchial fluid that fills 
the lungs. However, it does not speed fluid removal from the lung. A treatment that increases fluid 
removal from alveoli, to complement atropine-induced cessation of production, could speed up the 
return of effective oxygen exchange and improve resuscitation. Salbutamol can accelerate alveolar fluid 
clearance by enhancing salt and water transfer across alveolar and distal airways.[16] It may reverse 
OP insecticide induced bronchoconstriction, improving respiratory mechanics by decreasing airflow 
resistance and peak airway pressures and increasing dynamic compliance.[17] Animal studies have 
shown that salbutamol reverses OP insecticide-induced bronchoconstriction.[18, 19] 
 
A nebulised dose of salbutamol – available widely in LMIC rural hospitals - might be able to access the 
alveolar epithelium and increase the rate of fluid removal after OP poisoning. Therefore, a transient 
effect of nebulised salbutamol should not be a limitation since co-administered atropine will stop fluid 
production before salbutamol’s effect wears off. Although intravenous (IV) salbutamol might be better 
able to reach the alveoli in patients with bronchorrhoea, we selected the nebulised route for this first 
study due to safety considerations and wide availability of nebulisers.  
 
We therefore performed a pilot proof of concept dose response randomised controlled trial (RCT) using 
two doses of nebulised salbutamol to test its ability to speed the resuscitation of OP insecticide 
poisoned patients. Subsequent studies will be required to assess different dosing regimens before 
moving, if the data support it, into a large phase III RCT. 
 
 
 
 
 
 
 
 
 
 METHODS 
This dose-response phase II RCT was a feasibility and proof of concept pilot study conducted in the 
Department of Medicine at the Sylhet M. A. G. Osmani Medical College Hospital (SOMCH), Sylhet, 
Bangladesh. Ethics approval was received from the SOMC research ethics review committee. Written 
informed consent was taken in their own language from each patient or their relative (for unconscious 
patients and those under 16 years). The trial was registered (NCT02160548) at clinicaltrials.gov. 
Participants 
We approached all patients with OP insecticide self-poisoning admitted to the adult wards that required 
standard resuscitation with atropine, oxygen and fluids. Exclusion criteria were age <12 years, patient 
not requiring atropine or oxygen, prior receipt of atropine and lack of informed consent. The OP 
insecticide was identified from the history, the empty bottle brought in by the patient or relative, and/or 
from the patient/relative identifying the pesticide on a chart showing all locally available OP insecticides.  
Outcome, objectives and hypotheses 
The primary aim was to test the efficacy of salbutamol at improving oxygenation over the first 60 min of 
resuscitation. Our hypothesis was that addition of the beta-adrenergic agonist salbutamol to standard 
care and atropine would improve oxygenation and speed resuscitation. Secondary outcomes included 
heart rate, incidence of dysrhythmias, time to ‘atropinisation’, atropine dose required for resuscitation, 
incidence of aspiration or pneumonia, and mortality. 
Randomisation and allocation 
Patients were randomised into three study arms to receive nebulised salbutamol 5 mg (Salb5) or 2.5 
mg (Salb2.5), or saline 5 mL as placebo (NoSalb). Randomisation and allocation sequence generation 
were done independently by a clinician who was not associated with the care or assessment of the 
patients by means of a random number table. Allocations were concealed in sequentially numbered, 
opaque, sealed envelopes.  
 In this RCT, the nebulized salbutamol or saline was not masked to the research clinician. However, the 
primary outcome (oxygen saturations) was recorded using an objective automated method; the study 
staff was not able to influence the recording of these data. Data analysis was done masked to 
allocation. Randomisation occurred after baseline data had been entered, and could not be altered by 
study doctors. The recruiting doctor could not predict allocation before randomisation. 
 
Intervention and study drugs 
Patients were seen by study doctors within 30 min of admission and treated as per standard 
management guidelines with doubling doses of atropine until a clinical response.[20] All patients 
received standard oxygen supplement, 4 litre/min via nasal mask until full atropinisation and vital 
stability. The aims for full atropinisation were to produce a clear chest on auscultation with no wheeze, 
heart rate >80 beats/min, pupils no longer pin point, dry axillae and systolic blood pressure >80 mm of 
Hg. Patients did not receive any atropine or pralidoxime before enrolled to this study. The initial dose of 
atropine was usually three ampules (1.8 mg), which was then doubled to 6, 12, and 24 ampule doses in 
every five minutes interval if there was no response. A partial response would result in a similar dose, 
rather than a doubling dose, being administered. All patients received pralidoxime iodide 1 g IV as a 
single dose.  Due to the dearth of intensive care beds in the hospital, intubation and ventilation were 
rarely available and patients were managed on open adult medical wards with a dedicated cardiac 
monitor (Infunix; IP-4050). Readings for peripheral oxygen saturations and heart rate were recorded 
automatically every minute; screen shots were taken every ten minutes to provide hard records of data 
for each ten min period. 
Patients received a single nebulised dose of salbutamol or saline immediately after the first dose of IV 
atropine. Salbutamol sulphate (5 mg/mL vials, Ventolin respirator solution, GlaxoSmithkline, UK), 0.9% 
sodium chloride for infusion (saline), atropine sulphate (0.6 mg/mL ampules, Chemist laboratories, BD) 
and pralidoxime iodide (500 mg/20 mL ampules, Hindustan medicines, India) were purchased locally. 
 
Sample size 
No similar study has been previously performed; therefore, no data were available that could be used to 
generate a sample size calculation. This study was designed to provide initial data on efficacy and 
safety that would allow the design of a larger phase III study of nebulised salbutamol or a similar scale 
study assessing IV salbutamol. We aimed to enrol 25 patients into each study arm (total 75 patients). 
We are aware that the marked variability in the clinical syndrome and severity produced by different OP 
insecticides would confound the results.[21] However, we believed that this size trial was both practical 
and useful for initiating a set of studies on salbutamol in OP insecticide poisoning. 
 
Statistical analysis  
Graphpad Prism v 7.0 was used for analysis. Demographic factors and clinical characteristics were 
summarised with counts (%) for categorical variables and median (interquartile range [IQR]) for 
continuous variables, as none was expected to be normally distributed. The main analysis was carried 
out on an intention-to-treat basis. For the primary outcome, we compared the mean area-under-the-
curve (AUC, calculated by Prism using the trapezoid method) value of oxygen saturations between 
three arms using a one-way ANOVA test. The AUC0-60min was based on a saturation of 70%, the lowest 
admission saturation in a patient who survived (with sensitivity analyses revising the baseline to 60% 
and 80%). We also did post-hoc analysis in Prism assessing (log-rank Mantel-Cox test) time to 
sustained saturations > 95 %, censored at 60 minutes or death. For non-parametric secondary 
outcomes, all groups were compared using a Kruskal–Wallis test; if significant, we then planned to 
perform pairwise comparisons with a non-parametric Mann–Whitney test. For parametric outcomes, we 
compared the odds ratios across the pairs. 
  
Role of the funding source: 
The funding source had no role in study design, data collection, data analysis, and data interpretation; 
or writing of the report; or in the decision to submit for publication. The corresponding author had full 
access to all the data in the study and had final responsibility for the decision to submit for publication. 
 
RESULTS 
 
From 1st Oct 2013 to 1st Dec 2015, 158 patients with acute symptomatic OP insecticide self-poisoning 
were assessed on admission to SOMCH. Eighty-three were excluded from the study (figure 1) while 
seventy-five were consented and randomised into the trial: 25 to saline placebo (NoSalb), 25 to 
salbutamol 2.5 mg (Salb2.5), and 25 to salbutamol 5 mg (Salb5), in addition to usual care. 
 
Baseline characteristics 
Patient groups were broadly similar at baseline in this pilot study (table 1), although a greater number of 
Salb5 patients had consumed the more toxic WHO Class Ib insecticides (Salb5 52%, Salb2.5 32%, 
NoSalb 24%). Clinically, more Salb5 patients had GCS <7/15 (figure 2) although NoSalb patients had 
lower mean oxygen saturations at baseline (table 1). According to the Peradeniya Organophosphorus 
Poisoning (POP) severity scale [22], a higher number (p<0.001) of moderately poisoned patients were 
recruited to the Salb5 group compared to NoSalb (64% vs 28%); although there was a similar number 
of severely poisoned patients across groups (figure 2). The mean heart rate in the Salb5 group was 
modestly higher than the other two groups (table 1). Time to presentation was similar across the three 
groups (figure 3) with four outliers in the Salb2.5 (one) and Salb5 (three) groups. 
 
  
Primary outcome – oxygen saturations 
Mean peripheral blood oxygen saturations improved more rapidly in NoSalb and Salb2.5 groups, 
reaching 95.0% by 16 and 18 min respectively, than in the Salb5 group, which transiently reached 
95.0% at 30 min before dipping down to the low 90s for the remaining 30 min (figure 4A). The median 
(IQR) area-under-the-curve (AUC) for peripheral oxygen saturations over the first 60 minutes, using 
70% as the baseline, was similar for all three groups: 1376 (95% CI 1282 to 1470), 1395 (1305 to 
1486), and 1233 (1100 to 1367) for NoSalb, Salb2.5 and Salb5 groups, respectively (ANOVA across all 
three groups, p=0.9898; figure 4B). Revising the baseline to 60% or 80% in a sensitivity analysis had 
no effect on the results. Again, on post-hoc analysis assessing time to saturation >95%, no difference 
(p=0.2963) was seen between study groups (figure 5). 
 
Secondary outcomes 
The median time for atropinisation and the median dose of atropine required for full atropinisation in 
each arm was the same, at 15 minutes and 12.6 mg (or 21 ampules), respectively (table 2, p=0.4805 
and p=0.1871 by Kruskal-Wallis, table 2). The mean heart rate increased across all three arms initially, 
before falling back towards 100 bpm at 10 min (figure 4C). The heart rate was consistently higher in the 
Salb5 group throughout resuscitation until the last 15 min when the mean Salb2.5 heart rate increased 
towards 115 bpm (figure 4C). The heart rates and rhythms were never hazardous. 
 
There were no differences in the incidence of aspiration pneumonia or NMJ dysfunction (intermediate 
syndrome) between the groups (table 2). Five (20%) NoSalb patients developed paralytic ileus 
compared to one (4%) in both Salb2.5 and Salb5 groups. The number of patients discharged without 
complications was similar between groups: 22 (88%) Salb5 vs 21 (84%) Salb2.5 vs 20 (80%) NoSalb 
patients (table 2). Three (12%) patients died in Salb2.5 and Salb5 groups while two (8%) patients died 
in the NoSalb group. All but one death occurred during resuscitation (figure 4D). 
 
DISCUSSION 
This RCT showed no apparent benefit from using a single 2.5 mg or 5 mg dose of nebulised salbutamol 
in addition to standard care in a tertiary level Bangladeshi hospital. Oxygenation over the first 60 min 
was non-significantly worse in the patients receiving nebulised salbutamol 5 mg compared to no 
salbutamol or salbutamol 2.5 mg despite similar doses of atropine and a similar time to atropinisation. 
As expected [23, 24], there was no indication of adverse cardiac effects of the nebulised salbutamol, 
although the heart rate of patients receiving salbutamol 5 mg was higher than the other groups for the 
first 45 min (suggesting possible systemic exposure). There was no trend for benefit for other 
secondary outcomes such as mortality, intermediate syndrome, or aspiration pneumonia, although the 
study was not powered to detect such differences.  
 
However, as expected due to the small size of the study, there was variation in severity between the 
three arms of the study with more sick patients in the higher dose of salbutamol arm. Much bigger 
studies designed using the data collected in this study and further phase II studies, and accounting for 
variation in OP compound and poisoning severity, will be required to answer the question of 
effectiveness. 
 
In a guinea pig study, Chavez et al showed immediate (5 minutes post intervention) benefit of using 
salbutamol 10 µg/kg by the intra-peritoneal (IP) route 90 minutes after parathion poisoning.[18] 
Administration of 2 mg/ml aerosolized salbutamol over 2 min also produced significant improvement 
(more than 50% reversion) of respiratory function lasting 5-10 min [19]. However, in both studies, 
animals did not receive atropine or any other treatment for parathion intoxication. The study was 
therefore quite different to the situation with poisoned humans and therefore of questionable relevance. 
We hypothesised that salbutamol might offer benefit over and above atropine by increasing the rate of 
fluid extraction from the alveoli through activation of epithelial sodium channel (ENaC) pumps and by 
treating bronchoconstriction, both of which should result in a lower requirement for atropine and a faster 
time to atropinisation and resuscitation. That neither occurred might suggest that sufficient salbutamol 
did not get to the alveoli, dissolving instead in the fluid filling the lungs. We did not differentiate our 
recording of bronchospasm and bronchorrhoea, so it is possible that the salbutamol effectively treated 
the bronchospasm while atropine dosing was continued for the alveoli bronchorrhoea. Oxygen 
saturations did not rise because the alveoli were filled with fluid. 
 
Intravenous salbutamol either as a bolus 250 mcg, or an infusion starting at 5 mcg/min, might be a 
more effective way of stimulating the alveoli channels. However, this also offers a greater likelihood of 
adverse effects than nebulised salbutamol. The BALTI trial used intravenous infusions of salbutamol for 
7 days (15mcg/kg/hr for up to seven days) but found it to be poorly tolerated, and possibly hazardous, 
in patients with acute respiratory distress syndrome (ARDS). The difference between ARDS and OP 
insecticide poisoning is that salbutamol treatment would only be required during acute resuscitation in 
the latter, reducing the risk of adverse effects. 
 
In this trial, the overall mortality was 10.6%, with no significant difference between the groups. A survey 
done in 2007 across Bangladesh reported a mortality of about 15% for OP poisoning [25]. The mortality 
in this study may have been lower due to chance or because of improved management, administration 
of atropine, and active monitoring of patients. Clinical trials can be useful to optimize and improve the 
management of OP poisoning. Unfortunately, ICU beds and mechanical ventilation were not available 
for patients in the study hospital - a problem widespread in Bangladesh and in other Asian district 
hospitals that see the majority of cases. Deaths occurred from acute respiratory failure due to a lack of 
resources. 
Limitations 
This study was a dose-response RCT, aiming to collect data that might allow further studies to be 
designed. Due to its size, it was not powered to detect modest differences in the incidence of death or 
respiratory complications. Since we found no evidence of improved oxygenation with high dose, there is 
no mechanistic indication that a small benefit may occur with this treatment. However, there is marked 
variability between OP insecticides in the clinical syndromes produced and severity of poisoning [21]; 
again, due to the small size of this pilot study, there were differences within the three groups in terms of 
the OPs involved and poisoning severity. This will have complicated the analysis of the oxygenation 
data and may have hidden a benefit for some patients. Due to the size of the study and therefore 
limited data, we also did not perform more refined time-dependent analysis and modelling. Much 
bigger, phase III RCTs will be required to control for the variation and to look for clinical benefit from 
salbutamol. Patients will need to be stratified on the basis of the OP insecticide ingested and severity of 
clinical features and cholinesterase inhibition, as done previously [26]. 
During resuscitation, several patients were restless, vomiting or defecating, and it was therefore difficult 
to maintain patient monitor probes attached continuously. This resulted in some missing data; however, 
since we took readings at one min intervals and used the AUC for the whole 60 min, we could still 
analyse the primary and key secondary outcomes. We could not intubate our patients whose GCS was 
less than seven due to lack of ICU facility, increasing mortality in the study. 
Conclusion: 
We found no evidence that nebulised salbutamol is likely to be beneficial at speeding atropinisation and 
resuscitation of poisoned patients, although the small size of the study and variation in poisoning 
severity due to variation in OP ingested, dose, and time to admission prevented small effects being 
noted. Management of such patients remains a great challenge [9, 10], especially in the resource-poor 
district hospitals in rural Asia that admit most patients. More evidence is required with which to guide 
therapy. Further studies of nebulised salbutamol or a pilot study of intravenous salbutamol until 
atropinisation is obtained may determine whether attempting to increase fluid removal from lungs is a 
viable therapeutic approach. Larger studies will then be required to determine whether salbutamol is 
beneficial to patients. 
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FIGURE LEGENDS 
 
Figure 1:  Trial Profile 
Flow diagram as per the CONSORT guidelines. Reasons for trial exclusion were not 
required atropine (n=29), not required oxygen (n=47), and did not give consent (n=7) 
 
Figure 2.  Glasgow Coma Scale (GCS) & Peradeniya Organophosphorus Poisoning (POP) 
severity scores on admission  
Median and IQR (black dots represent fatal cases). 
 
Figure 3 Time to presentation for patients across the three arms of the study 
 
Figure 4. Peripheral oxygen saturations and heart rate after administration of saline placebo 
or salbutamol 
A) Mean (SEM) and B) area-under-the-curve (AUC; using base of 70%), showing mean 
[IQR]) for peripheral oxygen saturation over the first 60 min for the three groups. 
Patients who died are marked with black dot. C) Mean (SEM) for heart rate over the first 
60 min for the three groups. D) Time to death for patients 
Figure 5.      Comparison of Time to event (Oxygen saturation >95%) analysis between the three     
arms of the study 
          
 
 
 
 
 Table 1. Baseline demographic and clinical characteristics 
 
 
 
 
A NoSalb 
(n=25) 
B    Salb2.5 
(n=25) 
 C     Salb5 
(n= 25) 
    
Age (years; median, IQR) 30 (20 to 44) 30 (19 to 44) 25 (21 to 36) 
Men (number; %) 13 (52%) 15 (60%) 16 (64%) 
    
Poisons ingested (number; %)    
WHO Class Ib toxicity (dichlorvos/ 
dicrotophos) 
6 (24%) 8 (32%) 13 (52%) 
WHO Class II toxicity (chlorpyrifos) 11 (44%) 10 (40%) 7 (28%) 
WHO Class III toxicity (malathion) 8 (32%) 7 (28%) 5 (20%) 
    
Time between poisoning and start of 
treatment (min; median, IQR) * 
263 (213 to 376) 205 (175 to 254) 246 (205 to 364) 
     < 120 mins (number; %) 0 (0) 2 (8%) 0 (0%) 
     120-240 mins (number; %) 11 (44%) 14 (56%) 11 (44%) 
     > 240 mins (number; %) 14 (56%) 8 (32%) 14 (56%) 
    
Clinical status on admission    
Oxygen saturations (%; mean, SD) 82.4 (15.2) 84.0 (12.3) 85.1 (12.3) 
Heart rate (bpm; mean, SD) 104.3 (21.3) 97.4 (19.6) 110.0 (22.5) 
Systolic BP (mmHg; mean, SD) 113.6 (15.2) 103.4 (13.9) 113.6 (24.9) 
Respiratory rate (RR; mean, SD) 20.3 (2.6) 20.8 (2.9) 22.2 (3.7) 
GCS (median, IQR) 10 (8 to 15) 13 (8 to 15) 12 (7 to 13) 
     GCS 14 or 15 (number; %) 9 (36%) 11 (44%) 5 (20%) 
     GCS 11 to 13 (number; %) 3 (12%) 2 (8%) 9 (36%) 
     GCS 7 to 10 (number; %) 12 (48%) 9 (36%) 5 (20%) 
     GCS 3 to 6 (number; %) 1 (4%) 3 (12%) 6 (24%) 
Peradeniya Organophosphorus Scale 
(POP) [22] 
   
Mild (0-3) 17 (68%) 13 (52%) 8 (32%) 
Moderate (4-7) 7 (28%) 11 (44%) 16 (64%) 
Severe (8-11) 1 (4%) 1 (4%) 1 (4%) 
Clinical features on admission    
Miosis (number; %) 25 (100%) 25 (100%) 25 (100%) 
Sweating (number; %) 25 (100%) 25 (100%) 25 (100%) 
Salivation (number; %) 25 (100%) 25 (100%) 25 (100%) 
Vomiting (number; %) 25 (100%) 23 (92%) 24 (96%) 
Bronchospasm (number; %) 24 (96%) 23 (92%) 22 (88%) 
Confusion (number; %) 14 (56%) 13 (52%) 14 (56%) 
Muscle weakness (number; %) 14 (56%) 12 (48%) 14 (56%) 
Lacrimation (number; %) 5 (20%) 7 (28%) 6 (24%) 
Diarrhoea (number; %) 1 (4%) 3 (12%) 4 (16%) 
Fasciculation (number; %) 0 (0%) 5 (20%) 3 (12%) 
Arrhythmia (number; %) 0 (0%) 2 (8 %) 4 (16%) 
Convulsion (number; %) 0 (0%) 0 (0%) 0 (0%) 
 
* Time of ingestion was not known for one patient in the Salb2.5 arm 
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Table 2. Summary of outcomes plus comparative statistics 
 
 
 
 
 
NoSalb 
(n=25) 
Salb2.5 
(n=25) 
Salb5 
(n= 25) 
 
 
Atropinisation       
Time required for full 
atropinisation (min; 
median, IQR) 
15.0 
(10 to 16) 
15.0 
(10 to 16) 
15.0 
(10 to 20) 
p=0.4805 (by Kruskal-Wallis) 
Dose of atropine required 
for atropinisation (mg; 
median, IQR) 
12.6 
(8.0 to 
13.4) 
12.6 
(9.3 to 
16.8) 
12.6 
(10.7 to 
20.6) 
p=0.1871 (by Kruskal-Wallis) 
Complications    
 
Aspiration pneumonia 
(number, %) 
1 (4%) 1 (4%) 1 (4%) 
Intermediate syndrome 
(number, %) 
0 (0%) 1 (4%) 1 (4%) 
Paralytic Ileus (number, 
%) 
5 (20%) 1 (4%) 1 (4%) 
Tachyarrhythmia (number, 
%) 
0 (0%) 0 (0%) 0 (0%) 
    
Outcome    
     Death 2 (8%) 3 (12%) 3 (12%) 
     Discharged without 
complication 
22 (88%) 21 (84%) 20 (80%) 
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Figure 1 
 
 
 
 
83 (52.5%) excluded 
         - 76 met exclusion criteria 
         -  7 refused to participate 
 
158 OP patients assessed for eligibility 
 
75 randomised 
 
25 allocated standard 
treatment (NoSalb) 
25 allocated standard 
treatment + 5 mg 
nebulized salbutamol single 
dose (Salb5) 
 
25 allocated standard 
treatment + 2.5 mg 
nebulized salbutamol 
single dose (Salb2.5) 
Protocol 
violation = 0 
25 received allocated 
treatment as per 
study protocol 
25 received allocated 
treatment as per 
study protocol 
25 received allocated 
treatment as per 
study protocol 
Protocol 
violation = 0 
Protocol 
violation = 0 
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Figure 2 
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Figure 3 
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Figure 4  
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Figure 5 
 
 
 
 
 
 
